nodes	percent_of_prediction	percent_of_DWPC	metapath
Pasireotide—SSTR3—nervous system—acquired immunodeficiency syndrome	0.00964	0.119	CbGeAlD
Pasireotide—SSTR3—central nervous system—acquired immunodeficiency syndrome	0.00928	0.114	CbGeAlD
Pasireotide—SSTR2—digestive system—acquired immunodeficiency syndrome	0.00838	0.103	CbGeAlD
Pasireotide—SSTR1—lung—acquired immunodeficiency syndrome	0.00823	0.101	CbGeAlD
Pasireotide—SSTR1—nervous system—acquired immunodeficiency syndrome	0.00762	0.0937	CbGeAlD
Pasireotide—SSTR3—brain—acquired immunodeficiency syndrome	0.00737	0.0906	CbGeAlD
Pasireotide—SSTR1—central nervous system—acquired immunodeficiency syndrome	0.00734	0.0902	CbGeAlD
Pasireotide—SSTR2—nervous system—acquired immunodeficiency syndrome	0.00648	0.0796	CbGeAlD
Pasireotide—SSTR2—central nervous system—acquired immunodeficiency syndrome	0.00624	0.0767	CbGeAlD
Pasireotide—SSTR1—brain—acquired immunodeficiency syndrome	0.00582	0.0716	CbGeAlD
Pasireotide—SSTR2—brain—acquired immunodeficiency syndrome	0.00495	0.0609	CbGeAlD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00232	0.00587	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00228	0.00576	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00223	0.00564	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00214	0.00541	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0021	0.00532	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.0021	0.00531	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.0021	0.00531	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.0021	0.00531	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00206	0.00521	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00204	0.00516	CbGpPWpGaD
Pasireotide—SSTR2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.00203	0.00514	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00201	0.00509	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00201	0.00509	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00196	0.00495	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00194	0.0049	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.0019	0.00481	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.0019	0.0048	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00188	0.00476	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00184	0.00467	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.0018	0.00456	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.00178	0.00451	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00178	0.00451	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00178	0.00451	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00177	0.00448	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00177	0.00448	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00177	0.00447	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00175	0.00443	CbGpPWpGaD
Pasireotide—SSTR3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00175	0.00442	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00173	0.00439	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00173	0.00437	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.0017	0.00429	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.0017	0.00429	CbGpPWpGaD
Pasireotide—SSTR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00167	0.00424	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00166	0.00419	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00165	0.00419	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00165	0.00416	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00165	0.00416	CbGpPWpGaD
Pasireotide—SSTR3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00164	0.00415	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.0016	0.00405	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.0016	0.00405	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.0016	0.00404	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00159	0.00401	CbGpPWpGaD
Pasireotide—SSTR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00157	0.00398	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00157	0.00397	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00153	0.00387	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.0015	0.00381	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.0015	0.00381	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.0015	0.00378	CbGpPWpGaD
Pasireotide—SSTR5—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00148	0.00376	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00148	0.00374	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00147	0.00372	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.00146	0.00369	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00145	0.00366	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00144	0.00364	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00143	0.00363	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00141	0.00356	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00141	0.00356	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00141	0.00356	CbGpPWpGaD
Pasireotide—Aspartate aminotransferase increased—Lamivudine—acquired immunodeficiency syndrome	0.0014	0.00268	CcSEcCtD
Pasireotide—Anaemia—Nelfinavir—acquired immunodeficiency syndrome	0.0014	0.00268	CcSEcCtD
Pasireotide—Anaemia—Stavudine—acquired immunodeficiency syndrome	0.0014	0.00267	CcSEcCtD
Pasireotide—SSTR5—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.0014	0.00353	CbGpPWpGaD
Pasireotide—Nasopharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.00139	0.00266	CcSEcCtD
Pasireotide—SSTR2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00139	0.00351	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00139	0.00351	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00138	0.00349	CbGpPWpGaD
Pasireotide—Anaemia—Abacavir—acquired immunodeficiency syndrome	0.00138	0.00263	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Lamivudine—acquired immunodeficiency syndrome	0.00137	0.00262	CcSEcCtD
Pasireotide—SSTR2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00137	0.00347	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00136	0.00343	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00136	0.00343	CbGpPWpGaD
Pasireotide—Abdominal distension—Lamivudine—acquired immunodeficiency syndrome	0.00135	0.00259	CcSEcCtD
Pasireotide—Decreased appetite—Amprenavir—acquired immunodeficiency syndrome	0.00135	0.00259	CcSEcCtD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00135	0.00341	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00135	0.00341	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00135	0.0034	CbGpPWpGaD
Pasireotide—Influenza—Lamivudine—acquired immunodeficiency syndrome	0.00135	0.00257	CcSEcCtD
Pasireotide—Fatigue—Amprenavir—acquired immunodeficiency syndrome	0.00134	0.00257	CcSEcCtD
Pasireotide—Vertigo—Abacavir—acquired immunodeficiency syndrome	0.00134	0.00256	CcSEcCtD
Pasireotide—Arthralgia—Nevirapine—acquired immunodeficiency syndrome	0.00133	0.00255	CcSEcCtD
Pasireotide—Myalgia—Nevirapine—acquired immunodeficiency syndrome	0.00133	0.00255	CcSEcCtD
Pasireotide—Hyperglycaemia—Ritonavir—acquired immunodeficiency syndrome	0.00132	0.00253	CcSEcCtD
Pasireotide—Oedema peripheral—Efavirenz—acquired immunodeficiency syndrome	0.00131	0.0025	CcSEcCtD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.0013	0.00328	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Didanosine—acquired immunodeficiency syndrome	0.00129	0.00247	CcSEcCtD
Pasireotide—Myalgia—Nelfinavir—acquired immunodeficiency syndrome	0.00129	0.00247	CcSEcCtD
Pasireotide—Arthralgia—Nelfinavir—acquired immunodeficiency syndrome	0.00129	0.00247	CcSEcCtD
Pasireotide—SSTR1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00129	0.00326	CbGpPWpGaD
Pasireotide—SSTR2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00129	0.00326	CbGpPWpGaD
Pasireotide—Myalgia—Stavudine—acquired immunodeficiency syndrome	0.00129	0.00246	CcSEcCtD
Pasireotide—Arthralgia—Stavudine—acquired immunodeficiency syndrome	0.00129	0.00246	CcSEcCtD
Pasireotide—Anxiety—Nelfinavir—acquired immunodeficiency syndrome	0.00129	0.00246	CcSEcCtD
Pasireotide—Anxiety—Stavudine—acquired immunodeficiency syndrome	0.00128	0.00245	CcSEcCtD
Pasireotide—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.00127	0.00244	CcSEcCtD
Pasireotide—Hyperglycaemia—Saquinavir—acquired immunodeficiency syndrome	0.00127	0.00243	CcSEcCtD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00127	0.00322	CbGpPWpGaD
Pasireotide—Back pain—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00243	CcSEcCtD
Pasireotide—Arthralgia—Abacavir—acquired immunodeficiency syndrome	0.00127	0.00242	CcSEcCtD
Pasireotide—Myalgia—Abacavir—acquired immunodeficiency syndrome	0.00127	0.00242	CcSEcCtD
Pasireotide—Anxiety—Abacavir—acquired immunodeficiency syndrome	0.00126	0.00241	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00126	0.00319	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00125	0.00317	CbGpPWpGaD
Pasireotide—Oedema peripheral—Delavirdine—acquired immunodeficiency syndrome	0.00125	0.00239	CcSEcCtD
Pasireotide—Alopecia—Indinavir—acquired immunodeficiency syndrome	0.00124	0.00237	CcSEcCtD
Pasireotide—Decreased appetite—Didanosine—acquired immunodeficiency syndrome	0.00124	0.00236	CcSEcCtD
Pasireotide—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.00123	0.00235	CcSEcCtD
Pasireotide—SSTR5—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00122	0.00309	CbGpPWpGaD
Pasireotide—Anaemia—Zidovudine—acquired immunodeficiency syndrome	0.00121	0.00232	CcSEcCtD
Pasireotide—Hyperglycaemia—Lamivudine—acquired immunodeficiency syndrome	0.00121	0.00232	CcSEcCtD
Pasireotide—SSTR3—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00121	0.00307	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00121	0.00306	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.0012	0.00303	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.0012	0.00303	CbGpPWpGaD
Pasireotide—Back pain—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00226	CcSEcCtD
Pasireotide—Vertigo—Zidovudine—acquired immunodeficiency syndrome	0.00118	0.00226	CcSEcCtD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00117	0.00297	CbGpPWpGaD
Pasireotide—Alopecia—Efavirenz—acquired immunodeficiency syndrome	0.00117	0.00224	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.00116	0.00222	CcSEcCtD
Pasireotide—SSTR1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00116	0.00294	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.00116	0.00222	CcSEcCtD
Pasireotide—Oedema peripheral—Ritonavir—acquired immunodeficiency syndrome	0.00116	0.00221	CcSEcCtD
Pasireotide—SSTR5—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00114	0.0029	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00114	0.00288	CbGpPWpGaD
Pasireotide—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.00114	0.00217	CcSEcCtD
Pasireotide—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.00113	0.00216	CcSEcCtD
Pasireotide—SSTR2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00113	0.00285	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.00113	0.00215	CcSEcCtD
Pasireotide—SSTR3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00113	0.00285	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.00112	0.00215	CcSEcCtD
Pasireotide—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.00112	0.00215	CcSEcCtD
Pasireotide—Alopecia—Delavirdine—acquired immunodeficiency syndrome	0.00112	0.00214	CcSEcCtD
Pasireotide—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.00112	0.00214	CcSEcCtD
Pasireotide—Myalgia—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00214	CcSEcCtD
Pasireotide—Arthralgia—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00214	CcSEcCtD
Pasireotide—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00112	0.00214	CcSEcCtD
Pasireotide—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.00112	0.00213	CcSEcCtD
Pasireotide—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.00112	0.00213	CcSEcCtD
Pasireotide—Anxiety—Zidovudine—acquired immunodeficiency syndrome	0.00111	0.00213	CcSEcCtD
Pasireotide—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.00111	0.00212	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.00111	0.00212	CcSEcCtD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.0011	0.00279	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.0011	0.00279	CbGpPWpGaD
Pasireotide—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.0011	0.00211	CcSEcCtD
Pasireotide—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.0011	0.0021	CcSEcCtD
Pasireotide—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.0011	0.0021	CcSEcCtD
Pasireotide—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.0011	0.0021	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00109	0.00276	CbGpPWpGaD
Pasireotide—SSTR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00108	0.00273	CbGpPWpGaD
Pasireotide—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.00108	0.00206	CcSEcCtD
Pasireotide—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.00107	0.00205	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00107	0.00271	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00107	0.00271	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00107	0.00271	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00107	0.00271	CbGpPWpGaD
Pasireotide—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.00107	0.00204	CcSEcCtD
Pasireotide—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.00107	0.00204	CcSEcCtD
Pasireotide—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00107	0.00204	CcSEcCtD
Pasireotide—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.00106	0.00203	CcSEcCtD
Pasireotide—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.00106	0.00202	CcSEcCtD
Pasireotide—SSTR2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00106	0.00267	CbGpPWpGaD
Pasireotide—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00105	0.00202	CcSEcCtD
Pasireotide—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.00105	0.002	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00105	0.00265	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.00104	0.002	CcSEcCtD
Pasireotide—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00199	CcSEcCtD
Pasireotide—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00199	CcSEcCtD
Pasireotide—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.00104	0.00198	CcSEcCtD
Pasireotide—Anxiety—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00198	CcSEcCtD
Pasireotide—SSTR5—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00103	0.00261	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00103	0.0026	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00103	0.0026	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00103	0.0026	CbGpPWpGaD
Pasireotide—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.00102	0.00195	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00102	0.00258	CbGpPWpGaD
Pasireotide—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00102	0.00195	CcSEcCtD
Pasireotide—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00101	0.00193	CcSEcCtD
Pasireotide—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00101	0.00193	CcSEcCtD
Pasireotide—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.00101	0.00193	CcSEcCtD
Pasireotide—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00101	0.00192	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.001	0.00254	CbGpPWpGaD
Pasireotide—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000998	0.00191	CcSEcCtD
Pasireotide—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000997	0.0019	CcSEcCtD
Pasireotide—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000994	0.0019	CcSEcCtD
Pasireotide—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.000992	0.0019	CcSEcCtD
Pasireotide—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000991	0.00189	CcSEcCtD
Pasireotide—SSTR2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000989	0.0025	CbGpPWpGaD
Pasireotide—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000988	0.00189	CcSEcCtD
Pasireotide—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.000983	0.00188	CcSEcCtD
Pasireotide—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000983	0.00188	CcSEcCtD
Pasireotide—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.000979	0.00187	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000978	0.00247	CbGpPWpGaD
Pasireotide—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000978	0.00187	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000977	0.00187	CcSEcCtD
Pasireotide—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000976	0.00187	CcSEcCtD
Pasireotide—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000975	0.00186	CcSEcCtD
Pasireotide—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000972	0.00186	CcSEcCtD
Pasireotide—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00097	0.00185	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000969	0.00245	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000964	0.00244	CbGpPWpGaD
Pasireotide—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000961	0.00184	CcSEcCtD
Pasireotide—SSTR5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000957	0.00242	CbGpPWpGaD
Pasireotide—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000953	0.00182	CcSEcCtD
Pasireotide—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000952	0.00182	CcSEcCtD
Pasireotide—SSTR2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000952	0.00241	CbGpPWpGaD
Pasireotide—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000951	0.00182	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000946	0.00239	CbGpPWpGaD
Pasireotide—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000944	0.0018	CcSEcCtD
Pasireotide—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.00094	0.0018	CcSEcCtD
Pasireotide—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.00094	0.0018	CcSEcCtD
Pasireotide—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000937	0.00179	CcSEcCtD
Pasireotide—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000932	0.00178	CcSEcCtD
Pasireotide—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000926	0.00177	CcSEcCtD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000924	0.00234	CbGpPWpGaD
Pasireotide—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000924	0.00177	CcSEcCtD
Pasireotide—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000918	0.00175	CcSEcCtD
Pasireotide—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000917	0.00175	CcSEcCtD
Pasireotide—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000917	0.00175	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000911	0.0023	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000911	0.0023	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00091	0.0023	CbGpPWpGaD
Pasireotide—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000909	0.00174	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000908	0.00174	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000907	0.0023	CbGpPWpGaD
Pasireotide—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000907	0.00173	CcSEcCtD
Pasireotide—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000904	0.00173	CcSEcCtD
Pasireotide—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000903	0.00173	CcSEcCtD
Pasireotide—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000902	0.00172	CcSEcCtD
Pasireotide—SSTR2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000894	0.00226	CbGpPWpGaD
Pasireotide—Headache—Didanosine—acquired immunodeficiency syndrome	0.00089	0.0017	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00089	0.00225	CbGpPWpGaD
Pasireotide—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000888	0.0017	CcSEcCtD
Pasireotide—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000885	0.00169	CcSEcCtD
Pasireotide—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000883	0.00169	CcSEcCtD
Pasireotide—SSTR2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000883	0.00223	CbGpPWpGaD
Pasireotide—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000882	0.00168	CcSEcCtD
Pasireotide—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000877	0.00168	CcSEcCtD
Pasireotide—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000875	0.00167	CcSEcCtD
Pasireotide—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000874	0.00167	CcSEcCtD
Pasireotide—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000873	0.00167	CcSEcCtD
Pasireotide—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000872	0.00167	CcSEcCtD
Pasireotide—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000869	0.00166	CcSEcCtD
Pasireotide—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000869	0.00166	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000868	0.00219	CbGpPWpGaD
Pasireotide—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000867	0.00166	CcSEcCtD
Pasireotide—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000867	0.00166	CcSEcCtD
Pasireotide—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000866	0.00166	CcSEcCtD
Pasireotide—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00086	0.00164	CcSEcCtD
Pasireotide—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00086	0.00164	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000858	0.00164	CcSEcCtD
Pasireotide—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000853	0.00163	CcSEcCtD
Pasireotide—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000852	0.00163	CcSEcCtD
Pasireotide—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000849	0.00162	CcSEcCtD
Pasireotide—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000847	0.00162	CcSEcCtD
Pasireotide—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000847	0.00162	CcSEcCtD
Pasireotide—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000844	0.00161	CcSEcCtD
Pasireotide—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000844	0.00161	CcSEcCtD
Pasireotide—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000842	0.00161	CcSEcCtD
Pasireotide—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000842	0.00161	CcSEcCtD
Pasireotide—SSTR2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000841	0.00213	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000841	0.00213	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00084	0.00212	CbGpPWpGaD
Pasireotide—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000837	0.0016	CcSEcCtD
Pasireotide—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000837	0.0016	CcSEcCtD
Pasireotide—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000834	0.00159	CcSEcCtD
Pasireotide—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000831	0.00159	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000821	0.00208	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000821	0.00157	CcSEcCtD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00082	0.00207	CbGpPWpGaD
Pasireotide—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000819	0.00156	CcSEcCtD
Pasireotide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000818	0.00156	CcSEcCtD
Pasireotide—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000816	0.00156	CcSEcCtD
Pasireotide—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000815	0.00156	CcSEcCtD
Pasireotide—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000815	0.00156	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000815	0.00206	CbGpPWpGaD
Pasireotide—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000812	0.00155	CcSEcCtD
Pasireotide—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000812	0.00155	CcSEcCtD
Pasireotide—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000806	0.00154	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000805	0.00204	CbGpPWpGaD
Pasireotide—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000804	0.00154	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000801	0.00203	CbGpPWpGaD
Pasireotide—Headache—Nevirapine—acquired immunodeficiency syndrome	0.0008	0.00153	CcSEcCtD
Pasireotide—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000798	0.00153	CcSEcCtD
Pasireotide—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000798	0.00153	CcSEcCtD
Pasireotide—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000796	0.00152	CcSEcCtD
Pasireotide—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000788	0.00151	CcSEcCtD
Pasireotide—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000787	0.0015	CcSEcCtD
Pasireotide—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000784	0.0015	CcSEcCtD
Pasireotide—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000784	0.0015	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000781	0.00198	CbGpPWpGaD
Pasireotide—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000779	0.00149	CcSEcCtD
Pasireotide—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000777	0.00148	CcSEcCtD
Pasireotide—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000775	0.00148	CcSEcCtD
Pasireotide—Headache—Stavudine—acquired immunodeficiency syndrome	0.000773	0.00148	CcSEcCtD
Pasireotide—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000773	0.00148	CcSEcCtD
Pasireotide—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000771	0.00147	CcSEcCtD
Pasireotide—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00077	0.00147	CcSEcCtD
Pasireotide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000769	0.00147	CcSEcCtD
Pasireotide—Headache—Abacavir—acquired immunodeficiency syndrome	0.000761	0.00145	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000759	0.00145	CcSEcCtD
Pasireotide—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000759	0.00145	CcSEcCtD
Pasireotide—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000758	0.00145	CcSEcCtD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000757	0.00191	CbGpPWpGaD
Pasireotide—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000754	0.00144	CcSEcCtD
Pasireotide—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00075	0.00143	CcSEcCtD
Pasireotide—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000745	0.00142	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000743	0.00188	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000737	0.00141	CcSEcCtD
Pasireotide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000735	0.0014	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000734	0.00186	CbGpPWpGaD
Pasireotide—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000734	0.0014	CcSEcCtD
Pasireotide—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000733	0.0014	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000731	0.0014	CcSEcCtD
Pasireotide—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000726	0.00139	CcSEcCtD
Pasireotide—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000725	0.00138	CcSEcCtD
Pasireotide—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000722	0.00138	CcSEcCtD
Pasireotide—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000719	0.00137	CcSEcCtD
Pasireotide—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000715	0.00137	CcSEcCtD
Pasireotide—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000715	0.00137	CcSEcCtD
Pasireotide—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000713	0.00136	CcSEcCtD
Pasireotide—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000713	0.00136	CcSEcCtD
Pasireotide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000709	0.00135	CcSEcCtD
Pasireotide—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000705	0.00135	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000704	0.00178	CbGpPWpGaD
Pasireotide—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000697	0.00133	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000697	0.00133	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000693	0.00175	CbGpPWpGaD
Pasireotide—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000692	0.00132	CcSEcCtD
Pasireotide—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000692	0.00132	CcSEcCtD
Pasireotide—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000686	0.00131	CcSEcCtD
Pasireotide—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000682	0.0013	CcSEcCtD
Pasireotide—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000682	0.0013	CcSEcCtD
Pasireotide—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000682	0.0013	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000679	0.00172	CbGpPWpGaD
Pasireotide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000676	0.00129	CcSEcCtD
Pasireotide—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000672	0.00128	CcSEcCtD
Pasireotide—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000666	0.00127	CcSEcCtD
Pasireotide—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000665	0.00127	CcSEcCtD
Pasireotide—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00066	0.00126	CcSEcCtD
Pasireotide—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000659	0.00126	CcSEcCtD
Pasireotide—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000659	0.00126	CcSEcCtD
Pasireotide—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000656	0.00125	CcSEcCtD
Pasireotide—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000654	0.00125	CcSEcCtD
Pasireotide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000647	0.00124	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000647	0.00164	CbGpPWpGaD
Pasireotide—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000645	0.00123	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000644	0.00163	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00064	0.00162	CbGpPWpGaD
Pasireotide—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000638	0.00122	CcSEcCtD
Pasireotide—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000637	0.00122	CcSEcCtD
Pasireotide—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000634	0.00121	CcSEcCtD
Pasireotide—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000634	0.00121	CcSEcCtD
Pasireotide—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000626	0.0012	CcSEcCtD
Pasireotide—Headache—Indinavir—acquired immunodeficiency syndrome	0.000625	0.00119	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000624	0.00158	CbGpPWpGaD
Pasireotide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000623	0.00119	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00062	0.00157	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000618	0.00156	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000618	0.00156	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000617	0.00156	CbGpPWpGaD
Pasireotide—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000617	0.00118	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000605	0.00153	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000605	0.00153	CbGpPWpGaD
Pasireotide—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000605	0.00116	CcSEcCtD
Pasireotide—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000599	0.00114	CcSEcCtD
Pasireotide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000598	0.00114	CcSEcCtD
Pasireotide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000596	0.00114	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000593	0.0015	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000593	0.0015	CbGpPWpGaD
Pasireotide—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000592	0.00113	CcSEcCtD
Pasireotide—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00059	0.00113	CcSEcCtD
Pasireotide—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00059	0.00113	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000585	0.00148	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00058	0.00147	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00058	0.00147	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000576	0.00146	CbGpPWpGaD
Pasireotide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000576	0.0011	CcSEcCtD
Pasireotide—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000573	0.0011	CcSEcCtD
Pasireotide—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00057	0.00109	CcSEcCtD
Pasireotide—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000568	0.00108	CcSEcCtD
Pasireotide—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000565	0.00108	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000561	0.00142	CbGpPWpGaD
Pasireotide—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00056	0.00107	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000559	0.00141	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000556	0.00141	CbGpPWpGaD
Pasireotide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000551	0.00105	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00055	0.00139	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00055	0.00139	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00055	0.00139	CbGpPWpGaD
Pasireotide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000549	0.00105	CcSEcCtD
Pasireotide—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000549	0.00105	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000548	0.00139	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000548	0.00138	CbGpPWpGaD
Pasireotide—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000541	0.00103	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000536	0.00136	CbGpPWpGaD
Pasireotide—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000535	0.00102	CcSEcCtD
Pasireotide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00053	0.00101	CcSEcCtD
Pasireotide—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00053	0.00101	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000527	0.00133	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000527	0.00133	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000526	0.00133	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000526	0.00133	CbGpPWpGaD
Pasireotide—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000524	0.001	CcSEcCtD
Pasireotide—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000522	0.000998	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000515	0.0013	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000515	0.0013	CbGpPWpGaD
Pasireotide—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00051	0.000975	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000507	0.00128	CbGpPWpGaD
Pasireotide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000506	0.000967	CcSEcCtD
Pasireotide—SSTR2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000505	0.00128	CbGpPWpGaD
Pasireotide—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000503	0.00096	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000497	0.00126	CbGpPWpGaD
Pasireotide—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000495	0.000946	CcSEcCtD
Pasireotide—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000487	0.00093	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000485	0.00123	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000485	0.00123	CbGpPWpGaD
Pasireotide—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000479	0.000916	CcSEcCtD
Pasireotide—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000477	0.000911	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000475	0.0012	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000475	0.0012	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000475	0.0012	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000467	0.00118	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000467	0.00118	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000461	0.00116	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000459	0.00116	CbGpPWpGaD
Pasireotide—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000455	0.000869	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000454	0.00115	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000449	0.00113	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000442	0.00112	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000439	0.00111	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000435	0.0011	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000431	0.00109	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000431	0.00109	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000418	0.00106	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000415	0.00105	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000412	0.00104	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000401	0.00101	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000398	0.00101	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000395	0.000999	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000392	0.000991	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000386	0.000976	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000382	0.000966	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000377	0.000953	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000366	0.000926	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000361	0.000914	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000361	0.000914	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000356	0.0009	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000356	0.0009	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000353	0.000892	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00035	0.000886	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000345	0.000874	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000331	0.000838	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000328	0.00083	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000326	0.000824	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000325	0.000821	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000325	0.000821	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000325	0.000821	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000323	0.000818	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00032	0.00081	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000311	0.000788	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000311	0.000788	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.0003	0.000758	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000296	0.000748	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000294	0.000743	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000276	0.000698	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000276	0.000698	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000271	0.000686	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000255	0.000645	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000255	0.000645	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000247	0.000625	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000243	0.000616	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00024	0.000606	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000237	0.000599	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000233	0.00059	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00023	0.000581	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000223	0.000563	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000218	0.000551	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000213	0.00054	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00021	0.000531	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000209	0.000528	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000207	0.000523	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000204	0.000516	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000194	0.00049	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000191	0.000483	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000189	0.000479	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000188	0.000476	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000185	0.000468	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000175	0.000442	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000171	0.000432	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000129	0.000325	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000128	0.000324	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000123	0.000312	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000123	0.00031	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000109	0.000277	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000109	0.000275	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000101	0.000255	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.0001	0.000254	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.56e-05	0.000191	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.25e-05	0.000183	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.43e-05	0.000163	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.93e-05	0.00015	CbGpPWpGaD
